Abstract:
This specification relates to use of peptides having a specific affinity to subtype 1 of PACAP (pituitary adenylate cyclase activating polypeptide) receptors, particularly MAX (67 amino acids), NSP (61 amino acids) and M 65 (46 amino acids). MAX and NSP act as agonists to PACAP type 1 receptors, and M 65 acts as an antagonist to PACAP type 1 receptors.
Abstract:
An emulsion composition comprising (i) an alkyl modified carboxyvinyl polymer, (ii) a C12-C28 higher alcohol that is solid at room temperature (e.g., 15 to 20 DEG C), and (iii) a silicone oil, wherein the (i) to (ii) ratio is 0.5 or below by weight.
Abstract:
A cosmetic composition comprising water, a waxy ester of a C18-C34 fatty acid with a C18-C44 higher alcohol, and at least one component usable in cosmetics, including an amphoteric surfactant, and optionally containing a C18-C34 higher fatty acid itself. The invention can provide an intermediate composition for cosmetics, such as foundation, lipstick or eye shadow, which are mild to the touch and have such physical and chemical characteristics as to permit stable preservation.
Abstract:
An antipruritic drug comprising a zinc-amino acid conjugate and an antipruritic composition containing 2.6 x 10-3 to 2.6 x 10-1M of said drug.
Abstract:
A process for producing hyaluronic acid having a viscosity average molecular weight of 500,000 or less by mechanically degradating a high molecular hyaluronic acid solution by a shear treatment.
Abstract:
An enzyme which acts on a peptide C-terminal/glycine adduct of formula (I), (wherein A represents a residue formed by removing an alpha -amino or imino group and an alpha -carboxyl group from a natural alpha -amino acid, and X represents a hydrogen atom or a residue of an amino acid derivative which combines with the N atom via a carbonyl group) to produce a peptide C-terminal/ alpha -hydroxyglycine adduct of formula (II), (wherein A and X are each as defined above), and another enzyme which acts on the compound of formula (II) to produce a C-terminal amidated peptide of formula (III), wherein A and X are each as defined above.
Abstract:
A C-terminus amidation enzyme composition of serum or blood plasma origin, which acts on a C-terminus glycine adduct represented by formula (I) (wherein A represents a residue other than alpha-amino or imino group and alpha-carboxyl group of a natural alpha-amino acid origin, and X represents a hydrogen atom or a residue of an amino acid derivative bound to the N atom via a carbonyl group) to produce a C-terminus amidation product represented by formula (II) (wherein A and X are as defined above) and glyoxylic acid, is disclosed. A process for preparing the composition and its use are also disclosed.
Abstract:
Escherichia coli characterized in that a capability thereof of forming acetate is at most one fifth that of wild type Escherichia coli, and a process for producing a useful substance by cultivating the Escherichia coli to a high density and recovering the substance.
Abstract:
A synthetic mica powder containing 75 to 99 % of fluorine based on the stoichiometric composition and/or having thin leaf-like particle edges, a process for its production, and cosmetics containing said powder. This powder does not release fluoride ion and/or the thin leaf-like particle surface can contain an oily substance in a sufficient amount to provide cosmetics having excellent spreadability, luster, adhesiveness, and moldability, giving an appearance with high saturation, and having high stability and safety.